# Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

> **NCT03867097** · PHASE2 · COMPLETED · sponsor: **Civi Biopharma, Inc.** · enrollment: 34 (actual)

## Conditions studied

- Raynaud Phenomenon Secondary to Systemic Sclerosis

## Interventions

- **DRUG:** Placebo IV infusion
- **DRUG:** Iloprost Injection, for intravenous use

## Key facts

- **NCT ID:** NCT03867097
- **Lead sponsor:** Civi Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-07
- **Primary completion:** 2019-08-06
- **Final completion:** 2019-08-06
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03867097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03867097, "Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03867097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*